JP6005701B2 - W/o/wエマルション製造装置及びw/o/wエマルションの製造方法 - Google Patents
W/o/wエマルション製造装置及びw/o/wエマルションの製造方法 Download PDFInfo
- Publication number
- JP6005701B2 JP6005701B2 JP2014186718A JP2014186718A JP6005701B2 JP 6005701 B2 JP6005701 B2 JP 6005701B2 JP 2014186718 A JP2014186718 A JP 2014186718A JP 2014186718 A JP2014186718 A JP 2014186718A JP 6005701 B2 JP6005701 B2 JP 6005701B2
- Authority
- JP
- Japan
- Prior art keywords
- emulsion
- cylinder
- dispersion film
- cylindrical body
- flow path
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008307 w/o/w-emulsion Substances 0.000 title claims description 114
- 238000004519 manufacturing process Methods 0.000 title claims description 73
- 239000006185 dispersion Substances 0.000 claims description 85
- 239000008346 aqueous phase Substances 0.000 claims description 55
- 239000012071 phase Substances 0.000 claims description 48
- 239000000839 emulsion Substances 0.000 claims description 46
- 238000003825 pressing Methods 0.000 claims description 35
- 239000007788 liquid Substances 0.000 claims description 25
- 239000000126 substance Substances 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000011148 porous material Substances 0.000 claims description 7
- 239000012466 permeate Substances 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 239000003643 water by type Substances 0.000 claims 1
- 239000003921 oil Substances 0.000 description 34
- 235000019198 oils Nutrition 0.000 description 34
- 238000010586 diagram Methods 0.000 description 17
- 239000004094 surface-active agent Substances 0.000 description 15
- 239000013543 active substance Substances 0.000 description 9
- 238000007789 sealing Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 7
- 238000004945 emulsification Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- -1 for example Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- NAALWFYYHHJEFQ-ZASNTINBSA-N (2s,5r,6r)-6-[[(2r)-2-[[6-[4-[bis(2-hydroxyethyl)sulfamoyl]phenyl]-2-oxo-1h-pyridine-3-carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC(O)=CC=1)C(=O)C(C(N1)=O)=CC=C1C1=CC=C(S(=O)(=O)N(CCO)CCO)C=C1 NAALWFYYHHJEFQ-ZASNTINBSA-N 0.000 description 2
- MWWSFMDVAYGXBV-FGBSZODSSA-N (7s,9s)-7-[(2r,4s,5r,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-FGBSZODSSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 235000008753 Papaver somniferum Nutrition 0.000 description 2
- 240000001090 Papaver somniferum Species 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 229960003109 daunorubicin hydrochloride Drugs 0.000 description 2
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 229960003265 epirubicin hydrochloride Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 229960001176 idarubicin hydrochloride Drugs 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000005288 shirasu porous glass Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 229940001584 sodium metabisulfite Drugs 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000002195 soluble material Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UKBBZNRSHOCRNP-UHFFFAOYSA-N 1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol;hydrochloride Chemical compound Cl.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 UKBBZNRSHOCRNP-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical compound OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 description 1
- FGBFEFJZYZDLSZ-UHFFFAOYSA-N 5,7-dimethoxy-2,3-dimethyl-2,3-dihydroinden-1-one Chemical compound COC1=CC(OC)=CC2=C1C(=O)C(C)C2C FGBFEFJZYZDLSZ-UHFFFAOYSA-N 0.000 description 1
- KFYRPLNVJVHZGT-UHFFFAOYSA-N Amitriptyline hydrochloride Chemical compound Cl.C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KFYRPLNVJVHZGT-UHFFFAOYSA-N 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000146493 Cryptotaenia japonica Species 0.000 description 1
- 235000004035 Cryptotaenia japonica Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- CTENFNNZBMHDDG-UHFFFAOYSA-N Dopamine hydrochloride Chemical compound Cl.NCCC1=CC=C(O)C(O)=C1 CTENFNNZBMHDDG-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- WUKZPHOXUVCQOR-UHFFFAOYSA-N N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960005119 amitriptyline hydrochloride Drugs 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- MKKYBZZTJQGVCD-XTCKQBCOSA-N arbekacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)CC[C@H]1N MKKYBZZTJQGVCD-XTCKQBCOSA-N 0.000 description 1
- 229940087147 arbekacin sulfate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229950005951 azasetron Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- HZFGMQJYAFHESD-UHFFFAOYSA-M bromfenac sodium Chemical compound [Na+].NC1=C(CC([O-])=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 HZFGMQJYAFHESD-UHFFFAOYSA-M 0.000 description 1
- 229960002716 bromfenac sodium Drugs 0.000 description 1
- 229960001050 bupivacaine hydrochloride Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FYBXRCFPOTXTJF-UHFFFAOYSA-N carteolol hydrochloride Chemical compound [Cl-].N1C(=O)CCC2=C1C=CC=C2OCC(O)C[NH2+]C(C)(C)C FYBXRCFPOTXTJF-UHFFFAOYSA-N 0.000 description 1
- 229960002165 carteolol hydrochloride Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001564 clomipramine hydrochloride Drugs 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229940109248 cromoglycate Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229960005316 diltiazem hydrochloride Drugs 0.000 description 1
- 229960001149 dopamine hydrochloride Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 description 1
- 229960002548 epinastine hydrochloride Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229960000868 fluvastatin sodium Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960003607 granisetron hydrochloride Drugs 0.000 description 1
- ZUXNZUWOTSUBMN-UHFFFAOYSA-N hydralazine hydrochloride Chemical compound Cl.C1=CC=C2C(NN)=NN=CC2=C1 ZUXNZUWOTSUBMN-UHFFFAOYSA-N 0.000 description 1
- 229960005384 hydralazine hydrochloride Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- QYZRTBKYBJRGJB-UHFFFAOYSA-N hydron;1-methyl-n-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)indazole-3-carboxamide;chloride Chemical compound Cl.C1=CC=C2C(C(=O)NC3CC4CCCC(C3)N4C)=NN(C)C2=C1 QYZRTBKYBJRGJB-UHFFFAOYSA-N 0.000 description 1
- XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 description 1
- 229960002102 imipramine hydrochloride Drugs 0.000 description 1
- MPGBPFMOOXKQRX-UHFFFAOYSA-N indenolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CC2 MPGBPFMOOXKQRX-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- LZULAZTXJLWELL-UHFFFAOYSA-N methyl hex-5-ynoate Chemical compound COC(=O)CCCC#C LZULAZTXJLWELL-UHFFFAOYSA-N 0.000 description 1
- VLPIATFUUWWMKC-UHFFFAOYSA-N mexiletine Chemical compound CC(N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-UHFFFAOYSA-N 0.000 description 1
- 229960001070 mexiletine hydrochloride Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- HWMFFWCDLWDYGX-UHFFFAOYSA-N n-(4-aminophenyl)furan-2-carboxamide Chemical compound C1=CC(N)=CC=C1NC(=O)C1=CC=CO1 HWMFFWCDLWDYGX-UHFFFAOYSA-N 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 1
- 229940043349 potassium metabisulfite Drugs 0.000 description 1
- 235000010263 potassium metabisulphite Nutrition 0.000 description 1
- BHZRJJOHZFYXTO-UHFFFAOYSA-L potassium sulfite Chemical compound [K+].[K+].[O-]S([O-])=O BHZRJJOHZFYXTO-UHFFFAOYSA-L 0.000 description 1
- 235000019252 potassium sulphite Nutrition 0.000 description 1
- 229960002789 procaterol hydrochloride Drugs 0.000 description 1
- 229960001187 propiverine hydrochloride Drugs 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229940066675 ricinoleate Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- 229960005480 sodium caprylate Drugs 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- JCQBWMAWTUBARI-UHFFFAOYSA-N tert-butyl 3-ethenylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(C=C)C1 JCQBWMAWTUBARI-UHFFFAOYSA-N 0.000 description 1
- MTKNGOHFNXIVOS-UHFFFAOYSA-N ticlopidine hydrochloride Chemical compound [H+].[Cl-].ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 MTKNGOHFNXIVOS-UHFFFAOYSA-N 0.000 description 1
- 229960002961 ticlopidine hydrochloride Drugs 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
- B01F23/40—Mixing liquids with liquids; Emulsifying
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F25/00—Flow mixers; Mixers for falling materials, e.g. solid particles
- B01F25/40—Static mixers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Colloid Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
本発明のW/O/Wエマルション製造方法は、第1筒体と前記第2筒体と導入部材との間に接続され、前記第1筒体と前記第2筒体と前記導入部材との間を流れる液体の流路を切替える流路切替部材を備えたW/O/Wエマルション製造装置を用いたW/O/Wエマルションの製造方法であって、前記第1筒体内に水相を封入した後、前記導入部材から第1分散膜を介して前記第1筒体内に油相を導入して油相中に水相が分散されたW/Oエマルションを得る第1工程と、前記第2筒体内に外水相となる水相を封入した後、前記流路切替部材の流路を切替えて前記第1筒体から前記第1分散膜より相対的に孔径が大きい前記第2分散膜を介して前記W/Oエマルションを前記第2筒体内に移動させることにより、W/O/Wエマルションを得る第2工程とを含むことを特徴とする。
図1は、本実施の形態に係るW/O/Wエマルション製造装置の断面模式図であり、図2Aは、本実施の形態に係るW/O/Wエマルション製造装置の平面図である。図1及び図2Aに示すように、本実施の形態に係るW/O/Wエマルション製造装置1は、筒軸方向において対向して配置された円筒状の第1筒体11及び第2筒体12を備える。この第1筒体11と第2筒体12との間には、板状の支持体(切替部材)13が配置される。第1筒体11及び第2筒体12は、例えば、ガラスなどにより構成される。支持体13は、例えば、樹脂材料などにより構成される。
次に、本発明の第2の実施の形態に係るW/O/Wエマルション製造装置について説明する。以下においては、上述した第1の実施の形態に係るW/O/Wエマルション製造装置との相違点を中心に説明する。また、同一の構成要素には同一の符号を付し、説明の重複を避ける。
次に、本発明の第3の実施の形態に係るW/O/Wエマルション製造装置について説明する。以下においては、上述した第1実施の形態に係るW/O/Wエマルション製造装置との相違点を中心に説明する。また、同一の構成要素には同一の符号を付し、説明の重複を避ける。
11,21,31 第1筒体
11a,21a,31a 第1押圧部材
12,22,32 第2筒体
12a,23,32a 第2押圧部材
22a 貫通孔
13 支持体
13a 第1分散膜
13b 第2分散膜
13c ゴム層
14a,14b 封止層
33 導入管
34 三方活栓
Claims (8)
- 内部に封入された液体が相互に移動可能な第1筒体及び第2筒体と、
前記第1筒体に油相を導入する導入部材と、
前記第1筒体と前記第2筒体と前記導入部材との間に接続され、前記第1筒体と前記第2筒体と前記導入部材との間を流れる液体の流路を切替える流路切替部材と、
前記第1筒体と前記流路切替部材との間の流路に設けられ、有用物質を含有する水相を透過して当該水相を油相中に分散させてW/Oエマルションとする第1分散膜と、
前記第2筒体と前記流路切替部材との間の流路に設けられ、前記第1分散膜より相対的に孔径が大きく、前記W/Oエマルションを透過して当該W/Oエマルションを水相中に分散させてW/O/Wエマルションとする第2分散膜と、を具備することを特徴とする、W/O/Wエマルション製造装置。 - 前記流路切替部材は、三方活栓である、
請求項1に記載のW/O/Wエマルション製造装置。 - 内部に封入された液体が相互に移動可能な第1筒体及び第2筒体と、
有用物質を含有する水相を透過して当該水相を油相中に分散させてW/Oエマルションとする第1分散膜と、
前記W/Oエマルションを透過して当該W/Oエマルションを水相中に分散させてW/O/Wエマルションとする第2分散膜と、
前記第1分散膜と前記第2分散膜との間で前記第1筒体と前記第2筒体との間を移動する液体を透過させる分散膜を切替える切替部材と、
前記第1筒体内に挿抜可能に配置され、前記第1筒体の筒軸方向に沿った貫通孔を有する第1押圧部材と、
前記第1押圧部材の前記貫通孔内に挿抜可能に配置され、外周面と前記第1押圧部材の先端面と前記第1筒体との間で囲まれた空間を形成する第2押圧部材と、
前記第1筒体の他端部に設けられ、前記第1筒体の径方向に沿った係止部材と、
を備えたことを特徴とする、W/O/Wエマルション製造装置。 - 前記第1筒体と前記第2筒体との間を移動する液体の単位時間当たりの移動量を略一定として前記W/O/Wエマルションを製造する、請求項1から請求項3のいずれか1項に記載のW/O/Wエマルション製造装置。
- 前記第2分散膜に設けられた孔の孔径が、10μm以上500μm以下である、請求項1から請求項4のいずれか1項に記載のW/O/Wエマルション製造装置。
- 前記有用物質が抗癌剤を含有する、請求項1から請求項5のいずれか1項に記載のW/O/Wエマルション製造装置。
- 前記油相がリピオドールを含有する、請求項1から請求項6のいずれか1項に記載のW/O/Wエマルション製造装置。
- 第1筒体と前記第2筒体と導入部材との間に接続され、前記第1筒体と前記第2筒体と前記導入部材との間を流れる液体の流路を切替える流路切替部材を備えたW/O/Wエマルション製造装置を用いたW/O/Wエマルションの製造方法であって、
前記第1筒体内に水相を封入した後、前記導入部材から第1分散膜を介して前記第1筒体内に油相を導入して油相中に水相が分散されたW/Oエマルションを得る第1工程と、
前記第2筒体内に外水相となる水相を封入した後、前記流路切替部材の流路を切替えて前記第1筒体から前記第1分散膜より相対的に孔径が大きい前記第2分散膜を介して前記W/Oエマルションを前記第2筒体内に移動させることにより、W/O/Wエマルションを得る第2工程とを含むことを特徴とする、W/O/Wエマルションの製造方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014186718A JP6005701B2 (ja) | 2014-09-12 | 2014-09-12 | W/o/wエマルション製造装置及びw/o/wエマルションの製造方法 |
PCT/JP2015/074982 WO2016039239A1 (ja) | 2014-09-12 | 2015-09-02 | W/o/wエマルション製造装置 |
TW104129906A TWI562825B (en) | 2014-09-12 | 2015-09-10 | W/o/w emulsion producing device |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014186718A JP6005701B2 (ja) | 2014-09-12 | 2014-09-12 | W/o/wエマルション製造装置及びw/o/wエマルションの製造方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016059828A JP2016059828A (ja) | 2016-04-25 |
JP6005701B2 true JP6005701B2 (ja) | 2016-10-12 |
Family
ID=55458988
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014186718A Active JP6005701B2 (ja) | 2014-09-12 | 2014-09-12 | W/o/wエマルション製造装置及びw/o/wエマルションの製造方法 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP6005701B2 (ja) |
TW (1) | TWI562825B (ja) |
WO (1) | WO2016039239A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI569861B (zh) * | 2016-04-22 | 2017-02-11 | 國立高雄大學 | 血液吸附分離材料、血液過濾裝置及其操作方法 |
JP7450146B2 (ja) | 2019-10-16 | 2024-03-15 | エス・ピー・ジーテクノ株式会社 | 円盤状多孔質膜ホルダー |
CN116240094B (zh) * | 2023-05-08 | 2023-08-04 | 北京纳通医疗科技控股有限公司 | 分离装置和svf的制备方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH082416B2 (ja) * | 1988-09-29 | 1996-01-17 | 宮崎県 | エマルションの製造方法 |
JP4113990B2 (ja) * | 1996-07-05 | 2008-07-09 | 宮崎県 | 抗癌剤含有乳化製剤及びその製造方法 |
DE19933441A1 (de) * | 1999-07-16 | 2001-01-18 | Bayer Ag | Verstellbarer Strahldispergator zur Herstellung wäßriger 2-Komponenten-Polyurethanlack-Emulsionen |
JP2001179077A (ja) * | 1999-12-24 | 2001-07-03 | Sunstar Inc | 多相エマルジョン |
US20010016703A1 (en) * | 1999-12-29 | 2001-08-23 | John Wironen | System for reconstituting pastes and methods of using same |
JP3435387B2 (ja) * | 2000-06-16 | 2003-08-11 | エス・ジーエンジニアリング株式会社 | 物質の微粒化装置 |
DE10333384B4 (de) * | 2003-07-23 | 2008-03-06 | Sigrid Heide | Mischanordnung zum Herstellen flüssiger oder halbfester Produkte |
JP4534123B2 (ja) * | 2003-12-26 | 2010-09-01 | エス・ピー・ジーテクノ株式会社 | エマルション調製用デバイス及び方法 |
EP1830952A2 (en) * | 2004-11-17 | 2007-09-12 | Velocys Inc. | Process for making or treating an emulsion using microchannel technology |
KR101307599B1 (ko) * | 2006-01-17 | 2013-09-12 | 박스터 헬쓰케어 에스에이 | 혼합용 장치, 시스템 및 방법 |
CN101683592B (zh) * | 2008-09-28 | 2011-12-14 | 中国科学院过程工程研究所 | 一种膜乳化器以及乳液制备方法 |
WO2010110118A1 (ja) * | 2009-03-23 | 2010-09-30 | コニカミノルタホールディングス株式会社 | リポソームの製造方法 |
GB201014514D0 (en) * | 2010-09-01 | 2010-10-13 | Biocomposites Ltd | Mixing and dispensing apparatus for bone void filler |
WO2013133209A1 (ja) * | 2012-03-06 | 2013-09-12 | 塩野義製薬株式会社 | エマルション調製用デバイス及びエマルション調製方法 |
-
2014
- 2014-09-12 JP JP2014186718A patent/JP6005701B2/ja active Active
-
2015
- 2015-09-02 WO PCT/JP2015/074982 patent/WO2016039239A1/ja active Application Filing
- 2015-09-10 TW TW104129906A patent/TWI562825B/zh active
Also Published As
Publication number | Publication date |
---|---|
WO2016039239A1 (ja) | 2016-03-17 |
JP2016059828A (ja) | 2016-04-25 |
TWI562825B (en) | 2016-12-21 |
TW201615264A (zh) | 2016-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5196760B2 (ja) | W/o/w型エマルジョン組成物 | |
JP6005701B2 (ja) | W/o/wエマルション製造装置及びw/o/wエマルションの製造方法 | |
JP4929158B2 (ja) | 難水溶性薬物を含有する医薬組成物 | |
US20120003288A1 (en) | Dispersion composition and method for manufacturing dispersion composition | |
CN108309413A (zh) | 用于超声检查成像的方法和装置 | |
EP3104840B1 (en) | Parenteral compositions of celecoxib | |
KR20110079675A (ko) | 세라미드 분산물 및 그 제조방법 | |
WO2017217337A1 (ja) | 泡沫、スクリーンフォーマー用の組成物、およびその評価方法 | |
JP6541252B2 (ja) | 医薬用乳化製剤及びその製造方法 | |
JP4113990B2 (ja) | 抗癌剤含有乳化製剤及びその製造方法 | |
KR102174176B1 (ko) | 다중 미립구체 제조장치 및 제조방법 | |
JPWO2018131620A1 (ja) | 薬物含有脂肪乳剤およびその製造方法 | |
US11571385B2 (en) | Self-emulsifiable composition, production method therefor, nanoemulsion, and production method therefor | |
ES2223571T3 (es) | Emulsion de cisplatino parenteral. | |
JP2011157321A (ja) | 分散組成物及び分散組成物の製造方法 | |
JP2009269888A (ja) | セラミド分散組成物の製造方法及びセラミド分散組成物 | |
JP2013224314A (ja) | セラミド分散組成物の製造方法及びセラミド分散組成物 | |
TW200416053A (en) | Fluid-jet pens configured for making modulated release bioactive agents | |
JPH02273619A (ja) | 脂溶性薬物含有水性液 | |
JP4894119B2 (ja) | 脂肪酸含有リポソーム分散液 | |
KR20190022020A (ko) | 친수성 세라마이드 복합체 및 유칼립투스 잎 추출물을 포함하는 화장료 조성물 제조방법 및 그 제조방법에 의해 제조한 화장료 조성물 | |
WO2005065677A1 (ja) | パクリタキセルまたはドセタキセルを溶解または分散させるための脂肪乳剤 | |
KR101889411B1 (ko) | 표적지향형 리포좀 | |
JP2005272536A (ja) | オリゴ糖と油脂の可溶化様混合物と乳化型エマルション | |
CN107708669A (zh) | 用于肠胃外给药的丙泊酚乳液 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160208 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160510 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160616 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160809 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160907 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6005701 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |